Prostate Cancer | Specialty

Poll: Vote on the Top Lung, GU Cancer Abstracts to Watch at ESMO 2025

September 22nd 2025

Vote in OncLive's polls to share which lung and genitournary cancer abstracts you're most anticipating at the 2025 ESMO Congress.

FDA Approves 2 Denosumab Biosimilars in High Fracture Risk Populations, Including in Breast and Prostate Cancer

September 17th 2025

Two denosumab biosimilars received approval from the FDA for the purpose of increasing bone mass in individuals at high risk for fracture.

From Growing Survivorship Programs to Practicing Self-Care: A Day in the Life With Oncologist Alicia Morgans, MD, MPH

September 10th 2025

Alicia Morgans, MD, MPH, shares her typical work week, the importance of saying yes to career opportunities, and the value of trusted team communication.

Dr Rathkopf on the Rationale for Evaluating Niraparib Plus Abiraterone Acetate in HRR+ mCSPC

September 9th 2025

Dana E. Rathkopf, MD, discusses the purpose of evaluating niraparib plus abiraterone acetate in metastatic castration-sensitive prostate cancer.

Dr Taub on the Benefits of a Multimodal Treatment Approach in Prostate Cancer

September 8th 2025

David Taub, MD, FACS, discusses how multidisciplinary care can optimize therapy selection for patients across different stages of prostate cancer.

The OncFive: Top Oncology Articles for the Week of 8/31

September 6th 2025

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

Dr McKay on the Rationale for Evaluating Radium-223 Plus Olaparib in mCRPC With Bone Metastases

September 5th 2025

Rana R. McKay, MD, discusses unmet needs in mCRPC that led to the inception of the COMRADE trial.

Dr Gellhaus on the Significance of Prostate Cancer Awareness Month

September 4th 2025

Paul Gellhaus, MD, discusses the clinical implications of prostate cancer screening in recognition of Prostate Cancer Awareness Month.

Dr Olmos on the Prognostic Implications of Data From the CAPTURE Study for BRCA-Mutant mHSPC

September 2nd 2025

David Olmos, MD, PhD, discusses the implications of data from the CAPTURE study for risk stratification in mHSPC harboring BRCA mutations.

FDA Approves New Denosumab Biosimilars for Osteoporosis and Cancer-Related Bone Disease

September 2nd 2025

OncLive’s August Roundup of Key FDA Approvals in Oncology: 3 Decisions to Know

September 2nd 2025

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

Five Under 5: Top Oncology Videos for the Week of 8/24

August 31st 2025

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.

The OncFive: Top Oncology Articles for the Week of 8/24

August 30th 2025

The FDA has cleared a 3-month subcutaneous depot formulation of leuprolide mesylate in prostate cancer, gedatolisib NDA is under review in breast cancer, and more.

FDA Approves 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer

August 29th 2025

The FDA has approved a 3-month version of leuprolide mesylate for patients with advanced prostate cancer.

Dr Qin on the Design of the HARMONY Trial of Niraparib-Based Therapy in mHSPC

August 28th 2025

Qian (Janie) Qin, MD, discusses the unique design of the phase 2 HARMONY trial of ​first-line niraparib plus abiraterone acetate and prednisone in mHSPC.

Dr Morgans on the Rationale for Evaluating Darolutamide Plus ADT in High-Risk Biochemical Recurrence of Prostate Cancer

August 27th 2025

Alicia Morgans, MD, MPH, discusses the background of darolutamide plus ADT in patients with prostate cancer with high-risk biochemical recurrence.

HRR Mutation Analysis Opens Door for Future Research Directions in Metastatic Prostate Cancer

August 25th 2025

David Olmos, MD, PhD, discusses how data on the incidence of HRR alterations in metastatic prostate cancer can inform future research.

Observational Study Associates BRCA and Other HRR Gene Alterations With Poorer Outcomes in mHSPC

August 24th 2025

David Olmos, MD, PhD, discusses CAPTURE study findings on the prevalence of HRR mutations in mHSPC, highlighting prognostic impact and outcomes.

Dr Wang on Evolving Challenges in the Management of CRPC

August 22nd 2025

Jue Wang, MD, discusses the evolving challenges in the management of castration-resistant prostate cancer.

Darolutamide Wins Canadian Approval for mCSPC

August 22nd 2025

Health Canada has granted marketing authorization to darolutamide for the treatment of adult patients with metastatic castration-sensitive prostate cancer.